DocWire News Editors

DocwireNews

In a study conducted presented at the 2021 American Society of Hematology Annual Meeting, researchers led by Aisha S. Patel, MBBS, MRCP, aimed to discern baseline demographics, symptoms, and survival outcomes of Waldenström macroglobulinaemia (WM) among different ethnic groups in the U.K.
“This first report on ethnic disparities in WM and non-IgM LPL in the U.K. identified key differences in presentation of disease. Ethnic minorities present at a younger age, with a lower paraprotein,” the researchers concluded. They added that further analysis exploring associations with socioeconomic status, deprivation indices, and comorbidities “are ongoing.”
As the researchers explained, approximately 400 patients are diagnosed with WM in the U.K. However, unlike in the U.S., WM outcomes between different ethnic groups are not well elucidated.
In this retrospective study, researchers reviewed data from the WMUK Rory Morrison Registry, which collates data on WM and non-IgM lymphoplasmacytic lymphoma (LPL) from 20 U.K. centers, diagnosed between June 1978 and May 2021. The analysis consisted of 732 patients with recorded ethnicity. The cohort was 90% White, and all others were collectively termed “Ethnic Minorities” (9%). Of this group, 56% were Asian, 27% were mixed-race, and 17% were Black.
The results showed that ethnic minorities presented with WM at a younger age compared to their White counterparts (60 vs. 64 years; p = 0.01) and had a significantly lower paraprotein at diagnosis (11 vs. 18 g/L; p = 0.05). MYD88 L265P mutation, which was tested in 34% of patients, was found to be positive in most White patients (87%), and notably less common in ethnic minority patients (p = 0.09), most significantly in the Asian cohort compared to White, the researchers noted. Moreover, the study found that the ethnic minorities cohort had a smaller proportion of WM diagnoses compared to White cohort (77% vs. 93%; p = 0.02), with the Asian cohort accounting for the highest proportion of non-IgM LPL (15% vs. 4%; p = 0.002).
In terms of survival, for ethnic minorities, at a median follow-up of seven years, 17 patients died (6% were considered disease-related), and the median overall survival was not reached. The investigators noted that the estimated five-year and 10- year rates of overall survival were 91% and 75%, respectively.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

Examining Racial Disparities in Treatment and Outcomes of Waldenström Macroglobulinemia Patients

ASH Annual Meeting and Exposition 2021

In a study conducted presented at the 2021 American Society of Hematology Annual Meeting, researchers led by Aisha S. Patel, MBBS, MRCP, aimed to discern baseline ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe